Elizabeth H. Cull
Expertise in
35
conditions

Dr. Elizabeth H. Cull

Oncology | Hematology Oncology
65 International Drive, 
Greenville, SC 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
35
conditions
65 International Drive, 
Greenville, SC 

Overview

Elizabeth Cull is an Oncologist and a Hematologist Oncology provider practicing medicine in Greenville, South Carolina.

Dr. Cull is highly rated in 35 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Cull is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 11 clinical trials. Dr. Cull is currently accepting new patients.

Specialties

Oncology
Hematology Oncology

Licenses

Internal Medicine in IL

Board Certifications

American Board Of Internal Medicine

Fellowships

Northwestern University Medical School

Hospital Affiliations

Prisma Health Greer Memorial Hospital
Prisma Health Greenville Memorial Hospital
Prisma Health Patewood Hospital
Prisma Health Hillcrest Hospital
Prisma Health Oconee Memorial Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Prisma Health Cancer Institute – Eastside
65 International Drive, Greenville, SC 29615

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Terminated
Publish Date: February 18, 2026
Intervention Type: Drug
Study Drug: HMPL-523
Study Phase: Phase 1
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Study Phase: Phase 3
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Withdrawn
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: APTO-253
Study Phase: Phase 1
Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma
Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: May 20, 2021
Intervention Type: Biological
Study Drugs: Rituximab, Obinutuzumab, Idelalisib, Ibrutinib, Bendamustine, TRU-016
Study Phase: Phase 1
View 9 Less Clinical Trials

16 Total Publications

Feasibility and Clinical Utility of Patient-Reported Outcome Measurement Information System-29 in a Newly Established Adolescent and Young Adult Oncology Program.
Feasibility and Clinical Utility of Patient-Reported Outcome Measurement Information System-29 in a Newly Established Adolescent and Young Adult Oncology Program.
Journal: Journal of adolescent and young adult oncology
Published: July 03, 2024
Similar Doctors
Expertise in
76
conditions
Dr. Britt H. Bolemon
Oncology | Hematology Oncology
Expertise in
76
conditions
Dr. Britt H. Bolemon
Oncology | Hematology Oncology
Referral required
Before you request

Prisma Health Cancer Institute – Eastside

65 International Drive, 
Greenville, SC 
 (0.1 miles away)
864-987-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Britt Bolemon is an Oncologist and a Hematologist Oncology provider practicing medicine in Greenville, South Carolina. Dr. Bolemon is highly rated in 76 conditions, according to our data. His clinical expertise encompasses Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Lung Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Bolemon is board certified in American Board Of Internal Medicine. Dr. Bolemon is currently accepting new patients.

Expertise in
40
conditions
Dr. Suzanne R. Fanning
Oncology | Hematology Oncology
Expertise in
40
conditions
Dr. Suzanne R. Fanning
Oncology | Hematology Oncology
Referral required
Before you request

Prisma Health Cancer Institute – Eastside

65 International Drive, 
Greenville, SC 
 (0.1 miles away)
864-987-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Suzanne Fanning is an Oncologist and a Hematologist Oncology provider practicing medicine in Greenville, South Carolina. Dr. Fanning is highly rated in 40 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Fanning is board certified in American Board Of Internal Medicine. Dr. Fanning is currently accepting new patients.

Expertise in
93
conditions
Dr. Steven A. Madden
Hematology Oncology | Hematology | Oncology
Expertise in
93
conditions
Dr. Steven A. Madden
Hematology Oncology | Hematology | Oncology
Referral may be required

Advanced Oncology Newberry

298 Commerce Dr, 
Newberry, SC 
 (56.1 miles away)
803-321-3232
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Madden is a Hematologist Oncology specialist and a Hematologist practicing medicine in Newberry, South Carolina. Dr. Madden is highly rated in 93 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Madden is currently accepting new patients.

Frequently Asked Questions about Dr. Elizabeth H. Cull

How do I make an appointment with Dr. Elizabeth H. Cull?

You can book an appointment with Dr. Elizabeth H. Cull by calling their office at 864-987-7000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elizabeth H. Cull a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elizabeth H. Cull is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elizabeth H. Cull specialize in?

While Dr. Elizabeth H. Cull is a Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Elizabeth H. Cull participate in research or clinical trials?

Yes. Dr. Elizabeth H. Cull has published 16 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Elizabeth H. Cull's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elizabeth H. Cull accept my insurance?

Dr. Elizabeth H. Cull accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 864-987-7000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cull's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 71 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile